Broncodilatadores
and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160:244-249. 16. Hanania NA, Sharafkhaneh A, Barber R, et al. `-agonist intrinsic efficacy. Measurement and clinical significance. Am J Respir Crit Care Med 2002; 165:1353-1358. 17. Ulrik CS, Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Eur Respir J 1994; 7:1003-1005. 18. Korosec M, Novak RD, Muers E, et al. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999; 107:209-213. 19. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13:988-992. 20. Jhonson M, Rennard S. Alternative mechanisms for long-acting ` 2-adrenergic agonists in COPD. Chest 2001; 120:258-270. 21. Ferguson GT, Funck-Brentano CG, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817-1824. 22. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152:838-860. 23. Nijkamp FP, Engels F, Henricks PAJ, et al. Mechanisms of `-adrenergic receptor regulation in lungs and its implications for the physiological responses. Physiol Rev 1992; 72: 323-367. 24. Johnson M. The `-adrenoceptor. Am J Respir Crit Care Med 1998; 158:S146-S153. 25. Ligget SB. The pharmacogenetics of ` 2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000; 105:S487-S492. 26. Palmer LJ, Silverman ES, Weiss ST, et al. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002; 165:861-866. 27. Hall IP. `2 adrenoceptor polymorphisms: are they clinically important? Thorax 1996; 51: 351-353.
28. Tan S, Hall IP, Dewar J, et al. Association between beta2-adrenoceptor and the response to long term beta 2-agonist therapy in asthma. Lancet 1997; 350:995-999. 29. Israel E, Drazen JM, Ligget SB, et al. The effect of polimorphisms of the ` 2-adrenergic re-ceptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80. 30. Taylor DR, Drazen JM, Herbison GO, et al. Asthma exacerbation during long term ` agonist use: influence of ` 2 adrenoceptor polimorphism. Thorax 2000; 55:762-767. 31. Picado Vallés C, Perpiñá Tordera M. Rinitis. Asma bronquial. En: Rozman C, Editor. Medicina Interna, 14.ª ed. Harcourt SA. Madrid. 2000. págs. 869-883. 32. Barnes PJ. Theophylline. New perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-818. 33. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 2000; 12:174-179. 34. Costello R. Pharmacology. En: Calverley PMA, MacNee W, Pride NB, Rennard SI, Editores. Chronic obstructive pulmonary disease, 2th ed. Arnold, London. 2003. págs. 341-356. 35. Torphy TJ, Compton CH, Marks MJ, et al. Phosphodi-esterase 4 inhibitors. En: Hansel TT, Barnes PJ, Editores. New drugs for asthma, allergy and COPD. Prog Respir Res. Karger. Basel. 2001; 31:321-325. 36. Roffel AF, Meurs H, Zaagsma J. Muscarinic receptors and the lung: relevance to chronic obstructive pulmonary disease and asthma. En: Barnes PJ, Buist AS, Editores. The role of anticholinergics in chronic obstructive pulmonary disease and chronic asthma. Gardiner-Caldwell. Cheshire. 1997. págs. 92-125. 37. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117:63S-66S.
305